Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azelastine
Drug ID BADD_D00198
Description Azelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic conjunctivitis.[L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.[L8240,L8270] Azelastine is also available in combination with fluticasone propionate as a nasal spray marketed under the trade name Dymista?, which is indicated for the symptomatic treatment of seasonal allergic rhinitis in patients 6 years of age and older.[L8309]
Indications and Usage For the symptomatic treatment of seasonal allergic rhinitis and non-allergic rhinitis, as well as symptomatic relief of ocular itching associated with allergic conjunctivitis.
Marketing Status Prescription; Discontinued
ATC Code R01AC03; R06AX19; S01GX07
DrugBank ID DB00972
KEGG ID D07483
MeSH ID C020976
PubChem ID 2267
TTD Drug ID D00JVR
NDC Product Code 65162-676; 50090-3833; 42291-094; 67877-477
Synonyms azelastine | 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone | Allergodil | Astelin | azelastine hydrochloride | 4-((4-chlorophenyl)methyl)-2- (hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)- phthalazinone HCl | Corifina | Loxin | Vividrin akut Azelastin | Optivar | Rhinolast | Optilast | Afluon | A 5610 | A-5610 | Azeptin
Chemical Information
Molecular Formula C22H24ClN3O
CAS Registry Number 58581-89-8
SMILES CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Ageusia07.14.03.003; 17.02.07.001--Not Available
Agitation17.02.05.012; 19.06.02.001--
Alanine aminotransferase increased13.03.01.003--
Albuminuria20.02.01.001--Not Available
Amenorrhoea05.05.01.002; 21.01.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Anosmia17.04.04.001; 22.04.03.006--
Anxiety19.06.02.0020.000142%
Aphthous ulcer07.05.06.002--Not Available
Application site irritation08.02.01.003; 12.07.01.003--Not Available
Arthritis15.01.01.001--
Asthenia08.01.01.001--Not Available
Asthma10.01.03.010; 22.03.01.002--Not Available
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Body temperature increased13.15.01.001--Not Available
Breast pain21.05.05.003--
Bronchitis11.01.09.001; 22.07.01.001--
Bronchospasm10.01.03.012; 22.03.01.004--
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.003--Not Available
Confusional state17.02.03.005; 19.13.01.001--
Conjunctivitis06.04.01.002; 11.01.06.012--
Constipation07.02.02.001--
Cough22.02.03.001--
Depressed level of consciousness17.02.04.0020.000142%
Dermatitis23.03.04.002--Not Available
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.004--Not Available
Diarrhoea07.02.01.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene